BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao X, Pang J, Li LY, Liu WP, Di JM, Sun QP, Fang YQ, Liu XP, Pu XY, He D. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene. 2010;29:4555-4566. [PMID: 20543870 DOI: 10.1038/onc.2010.213] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Yoon S, Rossi JJ. Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers. Curr Pharm Biotechnol 2018;19:604-10. [PMID: 29804529 DOI: 10.2174/1389201019666180528084059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Shimada K, Ishikawa T, Nakamura F, Shimizu D, Chishima T, Ichikawa Y, Sasaki T, Endo I, Nagashima Y, Goshima Y. Collapsin response mediator protein 2 is involved in regulating breast cancer progression. Breast Cancer 2014;21:715-23. [PMID: 23381229 DOI: 10.1007/s12282-013-0447-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
3 Umetsu S, Mizukami H, Saito T, Uchida C, Igawa A, Kudo K, Itabashi C, Osonoi S, Danyang G, Sasaki T, Yagihashi S, Hakamada K. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Sci Rep 2020;10:1156. [PMID: 31980687 DOI: 10.1038/s41598-020-57883-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen S, Zhang X, Peng J, Zhai E, He Y, Wu H, Chen C, Ma J, Wang Z, Cai S. VEGF promotes gastric cancer development by upregulating CRMP4. Oncotarget 2016;7:17074-86. [PMID: 26934554 DOI: 10.18632/oncotarget.7717] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
5 Geisler C, Gaisa NT, Pfister D, Fuessel S, Kristiansen G, Braunschweig T, Gostek S, Beine B, Diehl HC, Jackson AM, Borchers CH, Heidenreich A, Meyer HE, Knüchel R, Henkel C. Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. Biomed Res Int 2015;2015:454256. [PMID: 25667921 DOI: 10.1155/2015/454256] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
6 Kanda M, Nomoto S, Oya H, Shimizu D, Takami H, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res. 2014;33:66. [PMID: 25096402 DOI: 10.1186/s13046-014-0066-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
7 Li Y, Jin L, Ye F, Ma Q, Yang Z, Liu D, Yang J, Ma D, Gao Q. Isoform expression patterns of EPHA10 protein mediate breast cancer progression by regulating the E-Cadherin and β-catenin complex. Oncotarget 2017;8:30344-56. [PMID: 28427223 DOI: 10.18632/oncotarget.15910] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
8 Sato S, Nakamura F, Hiroshima Y, Nagashima Y, Kato I, Yamashita N, Goshima Y, Endo I. Caerulein-induced pancreatitis augments the expression and phosphorylation of collapsin response mediator protein 4. J Hepatobiliary Pancreat Sci 2016;23:422-31. [PMID: 27207309 DOI: 10.1002/jhbp.361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Li K, Pang J, Cheng H, Liu WP, Di JM, Xiao HJ, Luo Y, Zhang H, Huang WT, Chen MK, Li LY, Shao CK, Feng YH, Gao X. Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase. Oncotarget 2015;6:10030-44. [PMID: 25888628 DOI: 10.18632/oncotarget.3192] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
10 Yoneda A, Morgan-Fisher M, Wait R, Couchman JR, Wewer UM. A collapsin response mediator protein 2 isoform controls myosin II-mediated cell migration and matrix assembly by trapping ROCK II. Mol Cell Biol. 2012;32:1788-1804. [PMID: 22431514 DOI: 10.1128/mcb.06235-11] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
11 Tan F, Wahdan-Alaswad R, Yan S, Thiele CJ, Li Z. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma. Cancer Sci 2013;104:1586-92. [PMID: 24011394 DOI: 10.1111/cas.12278] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
12 Tan F, Thiele CJ, Li Z. Collapsin response mediator proteins: Potential diagnostic and prognostic biomarkers in cancers (Review). Oncol Lett 2014;7:1333-40. [PMID: 24765134 DOI: 10.3892/ol.2014.1909] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
13 Cai G, Wu D, Wang Z, Xu Z, Wong KB, Ng CF, Chan FL, Yu S. Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization. Oncogene 2017;36:546-58. [PMID: 27321179 DOI: 10.1038/onc.2016.227] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
14 Grant NJ, Coates PJ, Woods YL, Bray SE, Morrice NA, Hastie CJ, Lamont DJ, Carey FA, Sutherland C. Phosphorylation of a splice variant of collapsin response mediator protein 2 in the nucleus of tumour cells links cyclin dependent kinase-5 to oncogenesis. BMC Cancer 2015;15:885. [PMID: 26555036 DOI: 10.1186/s12885-015-1691-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
15 Yoon S, Rossi JJ. Emerging cancer-specific therapeutic aptamers. Curr Opin Oncol 2017;29:366-74. [PMID: 28692589 DOI: 10.1097/CCO.0000000000000389] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
16 Oya H, Kanda M, Sugimoto H, Shimizu D, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50:590-600. [PMID: 25173447 DOI: 10.1007/s00535-014-0993-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
17 Kanda M, Nomoto S, Oya H, Shimizu D, Takami H, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res. 2014;33:66. [PMID: 25096402 DOI: 10.1186/preaccept-2175168251300157] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Moutal A, White KA, Chefdeville A, Laufmann RN, Vitiello PF, Feinstein D, Weimer JM, Khanna R. Dysregulation of CRMP2 Post-Translational Modifications Drive Its Pathological Functions. Mol Neurobiol 2019;56:6736-55. [PMID: 30915713 DOI: 10.1007/s12035-019-1568-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
19 Yazawa K, Nakamura F, Masukawa D, Sato S, Hiroshima Y, Yabushita Y, Mori R, Matsuyama R, Kato I, Taniguchi H, Goshima Y, Endo I. Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer. Transl Oncol 2020;13:100746. [PMID: 32105991 DOI: 10.1016/j.tranon.2020.100746] [Reference Citation Analysis]
20 Fillmore RA, Kojima C, Johnson C, Kolcun G, Dangott LJ, Zimmer WE. New concepts concerning prostate cancer screening. Exp Biol Med (Maywood) 2014;239:793-804. [PMID: 24928864 DOI: 10.1177/1535370214539091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 Chen SL, Cai SR, Zhang XH, Li WF, Zhai ET, Peng JJ, Wu H, Chen CQ, Ma JP, Wang Z, He YL. Targeting CRMP-4 by lentivirus-mediated RNA interference inhibits SW480 cell proliferation and colorectal cancer growth. Exp Ther Med 2016;12:2003-8. [PMID: 27698685 DOI: 10.3892/etm.2016.3588] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
22 Liu W, Vivian CJ, Brinker AE, Hampton KR, Lianidou E, Welch DR. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey. Cancer Microenviron 2014;7:117-31. [PMID: 24938990 DOI: 10.1007/s12307-014-0148-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
23 Ponnusamy R, Lebedev AA, Pahlow S, Lohkamp B. Crystal structure of human CRMP-4: correction of intensities for lattice-translocation disorder. Acta Crystallogr D Biol Crystallogr 2014;70:1680-94. [PMID: 24914979 DOI: 10.1107/S1399004714006634] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
24 Pin E, Fredolini C, Petricoin EF 3rd. The role of proteomics in prostate cancer research: biomarker discovery and validation. Clin Biochem 2013;46:524-38. [PMID: 23266295 DOI: 10.1016/j.clinbiochem.2012.12.012] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
25 Ćetković H, Harcet M, Roller M, Bosnar MH. A survey of metastasis suppressors in Metazoa. Lab Invest 2018;98:554-70. [DOI: 10.1038/s41374-018-0024-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Li C, Xu H, Xiao L, Zhu H, Zhang G, Wei W, Li K, Cao X, Shen D, Holzbeierlein J, Li B. CRMP4a suppresses cell motility by sequestering RhoA activity in prostate cancer cells. Cancer Biol Ther 2018;19:1193-203. [PMID: 30081723 DOI: 10.1080/15384047.2018.1491507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 He YD, Luo ZH, Yang M, Ruan XX, Liu SY, Wu ZQ, Deng WM, Shao CK, Su ZL, He D, Gao X, Li LY. Prospective validation of DACH2 as a novel biomarker for prediction of metastasis and prognosis in muscle-invasive urothelial carcinoma of the bladder. Biochem Biophys Res Commun 2015;459:416-23. [PMID: 25744029 DOI: 10.1016/j.bbrc.2015.02.119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Maryáš J, Faktor J, Dvořáková M, Struhárová I, Grell P, Bouchal P. Proteomics in investigation of cancer metastasis: Functional and clinical consequences and methodological challenges. Proteomics 2014;14:426-40. [DOI: 10.1002/pmic.201300264] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
29 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
30 Guo H, Xia B. Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer. BMC Cancer 2016;16:565. [PMID: 27475326 DOI: 10.1186/s12885-016-2593-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
31 Bohl CR, Harihar S, Denning WL, Sharma R, Welch DR. Metastasis suppressors in breast cancers: mechanistic insights and clinical potential. J Mol Med (Berl) 2014;92:13-30. [PMID: 24311119 DOI: 10.1007/s00109-013-1109-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
32 Li C, Jiang W, Hu Q, Li LC, Dong L, Chen R, Zhang Y, Tang Y, Thrasher JB, Liu CB, Li B. Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis. Oncotarget 2016;7:22893-910. [PMID: 27014974 DOI: 10.18632/oncotarget.8290] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
33 Guo W, Zhang C, Feng P, Li M, Wang X, Xia Y, Chen D, Li J. M6A methylation of DEGS2, a key ceramide-synthesizing enzyme, is involved in colorectal cancer progression through ceramide synthesis. Oncogene 2021. [PMID: 34363020 DOI: 10.1038/s41388-021-01987-z] [Reference Citation Analysis]
34 Hiroshima Y, Nakamura F, Miyamoto H, Mori R, Taniguchi K, Matsuyama R, Akiyama H, Tanaka K, Ichikawa Y, Kato S, Kobayashi N, Kubota K, Nagashima Y, Goshima Y, Endo I. Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer. Ann Surg Oncol 2013;20 Suppl 3:S369-78. [PMID: 22805864 DOI: 10.1245/s10434-012-2491-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
35 Huang QX, Xiao CT, Chen Z, Lu MH, Pang J, Di JM, Luo ZH, Gao X. Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients. Asian J Androl 2018;20:56-61. [PMID: 28382925 DOI: 10.4103/aja.aja_3_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Gao X, Mao YH, Xiao C, Li K, Liu W, Li LY, Pang J. Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-κB/DNMT1 signaling pathway. Prostate 2018;78:682-90. [PMID: 29601651 DOI: 10.1002/pros.23512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
37 Zhou Y, Li R, Yu H, Wang R, Shen Z. microRNA-130a is an oncomir suppressing the expression of <i>CRMP4</i> in gastric cancer. Onco Targets Ther. 2017;10:3893-3905. [PMID: 28831264 DOI: 10.2147/ott.s139443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
38 Moreira JM, Cabezón T, Gromova I, Gromov P, Timmermans-Wielenga V, Machado I, Llombart-Bosch A, Kroman N, Rank F, Celis JE. Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. Mol Oncol 2010;4:539-61. [PMID: 21036680 DOI: 10.1016/j.molonc.2010.09.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
39 Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger HA, Brase JC, Kuner R, Schlomm T, Sauter G, Sültmann H, Korf U, Bokemeyer C, Walther R, Brümmendorf TH, Balabanov S. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res 2012;11:2452-66. [PMID: 22424448 DOI: 10.1021/pr201172n] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
40 Yang Y, Jiang Y, Xie D, Liu M, Song N, Zhu J, Fan J, Zhu C. Inhibition of cell-adhesion protein DPYSL3 promotes metastasis of lung cancer. Respir Res 2018;19:41. [PMID: 29514686 DOI: 10.1186/s12931-018-0740-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
41 Gao X, Li LY, Rassler J, Pang J, Chen MK, Liu WP, Chen Z, Ren SC, Zhou FJ, Xie KJ, Zhou X, Qian HJ, Bai XZ, Liu JM, Yang JG, He D, Shao CK, Su ZL, Wang J, Qiu JG, Ling L. Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases. J Natl Cancer Inst 2017;109. [PMID: 28122909 DOI: 10.1093/jnci/djw282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 2015;21:9838-9852. [PMID: 26379391 DOI: 10.3748/wjg.v21.i34.9838] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 61] [Article Influence: 12.8] [Reference Citation Analysis]
43 Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, Sahin E, Leng M, Fan C, Perou CM, Malovannaya A, Ellis MJ. DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 2018;115:E11978-87. [PMID: 30498031 DOI: 10.1073/pnas.1810598115] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
44 Li B, Li C. Suppression of Prostate Cancer Metastasis by DPYSL3-Targeted saRNA. In: Li L, editor. RNA Activation. Singapore: Springer; 2017. pp. 207-16. [DOI: 10.1007/978-981-10-4310-9_15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]